RT Journal Article
SR Electronic
T1 The impact of SARS-CoV-2 variants on the likelihood of children identified as sources of infection in the NIH workforce: a cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.07.23297422
DO 10.1101/2023.11.07.23297422
A1 van Loben Sels, Jessica M.
A1 Bailin, Heike B.
A1 Bell, Michael R.
A1 McCormick-Ell, Jessica
A1 Das, Sanchita
A1 Roder, Allison E.
A1 Ghedin, Elodie
A1 McGann, Michael
A1 Castel, Amanda D.
A1 Rebecca Prevots, D.
A1 Kwan, Jennifer L.
YR 2023
UL http://medrxiv.org/content/early/2023/11/08/2023.11.07.23297422.abstract
AB Background Children (<18 years old) were not initially considered significant sources of infection (SOIs) for SARS-CoV-2. Risk mitigation strategies were thus prioritized for adults, and vaccination was inaccessible for children until mid-2021. Emergence of novel variants led to significant increases in COVID-19 cases in both children and adults. Whether these emergence events and increased vulnerability of unvaccinated children had a synergistic effect resulting in increased caseloads in adults requires further exploration.Methods A retrospective cohort study was conducted among 3,545 workers diagnosed with COVID-19. Case details were compiled during contact investigations. Variants of concern were identified following sequencing of biological samples collected through employer-based testing programs. Logistic regression was performed to compare the odds of having a child SOI based on the dominant variant in the workforce.Results One-fourth (24.5%) of the cohort reported having a child in-residence; 11.2% identified a child as their SOI. In Alpha-dominant months, the odds of having a child SOI were 0.3, and the child SOI was likely older (5-17 years old). The odds of having a child SOI increased to 1.3 and 2.2 in Delta- and Omicron-dominant months, respectively. The odds of having younger child SOIs (<5 years old) were significantly higher in Omicron-dominant months.Conclusions Children were highly likely to acquire the virus and posed a significant risk of transmission to their adult caretakers during Delta- and Omicron-dominant months. Without proper mitigation strategies in both the home and the workplace, child-associated transmission can threaten operations in the forms of staff shortages.What is already known on this topic Increases in transmission trends related to SARs-CoV-2 Variants of Concern have been documented in the literature at the population level and in workplaces.What this study adds This study looks more closely at the role that children played in transmission to adult workers, and therefore their potential to seed transmission outside of the home. This interface of transmission has been neglected in the literature but is key for future policy development.How this study might affect research, practice, or policy Transmission of SARS-CoV-2 from children to their caretakers may cause significantly increased odds of infection in a worker population. This may have second order effects for staffing, particularly in workgroups with employees of childbearing age. Employers should consider this in the design of their policies for continuity of operations, telework, and leave.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Division of Intramural Research (DIR) of the NIAID/NIHAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Analysis was conducted using deidentified data that were collected for public health purposes and determined as exempted from IRB as assessed by both National Institutes of Health IRB and George Washington University IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAdjadjustedAZArizona, USABMIbody mass index, = kilograms/meters2CCNIH clinical centerCDCCenters for Disease Control and PreventionCIconfidence intervalCIRchild(ren) in-residenceCOVID-19Coronavirus disease 2019Ctcycle threshold, for PCR testingDLMDepartment of Laboratory MedicineDIRDivision of Intramural ResearchFDAFood and Drug Administration Group 0 – essential workersGroup A/Bnon-essential, priority workersGroup CteleworkersICindex case (NIH worker who reported a positive result)MDMaryland, USAMTMontana, USAmRNAmessenger ribonucleic acidNCNorth Carolina, USANIAIDNational Institutes of Allergy and Infectious DiseaseNIHNational Institutes of HealthNIEHSNational Institute of Environmental Health Sciences, campus located in NCNIDDKNational Institute of Diabetes and Digestive and Kidney Diseases, located in AZ Ns – not significant, p-value >0.05OMSOffice of Medical SafetyORodds ratioPCRpolymerase chain reactionPOIperiod of infectivityRefreference group, for regression analysesRMLRocky Mountain Labs, campus located in MTRWTGreturn-to-work group, either Group 0, Group A, Group B, or Group CSARS-CoV- 2severe acute respiratory syndrome coronavirus 2Sig.significance, p-values <0.5*, <0.01**, <0.001***, <0.0001****SOIsource of infectionTGrptime groupUTDup to date, defined as >14 days post-primary series OR >7 days post-booster doseVOCvariant of concern